and UK DRI at UCL have taken major steps forward in advancing MSH3-targeting therapies for Huntington's disease (HD). Their study is published in Science Translational Medicine. Using an HD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback